P. Twardowski

Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.

Stephen Gately, P. Twardowski, M. Sharon Stack et al. · PubMed · 1996 · 200 citations

Medicine, Biochemistry, Oncology +11

Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel

Heather H. Cheng, Roman Gulati, Arun Azad et al. · Prostate Cancer and Prostatic Diseases · 2015 · 83 citations · Full text

Medicine, Oncology, Pharmacology +15

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Maha Hussain, Joaquı́n Mateo, Karim Fizazi et al. · Annals of Oncology · 2019 · 82 citations

Medicine, Oncology, Pharmacology +17

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer

Joaquim Bellmunt, Bernhard J. Eigl, Elżbieta Senkus et al. · Annals of Oncology · 2017 · 27 citations · Full text

Medicine, Oncology, Pharmacology +6

Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy—California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial

Edna Cheung, David I. Quinn, Denice Tsao‐Wei et al. · Journal of Clinical Oncology · 2008 · 23 citations

Medicine, Pharmacology, Pharmacotherapy +14